Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

References

• MiddletonRJFoleyRNHegartyJThe unrecognized prevalence of chronic kidney disease in diabetesNephrol Dial Transplant200621889216221715
   PubMed Web of Science ®Google Scholar
• DeFronzoRATobinJDRoweJWAndresRGlucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulinJ Clin Invest197862425435353075
   PubMed Web of Science ®Google Scholar
• ScottDDavidsonJAManaging chronic kidney disease in type 2 diabetes in family practiceJ Natl Med Assoc201110395295922364065
   PubMed Web of Science ®Google Scholar
• TargherGChoncholMPichiriIZoppiniGRisk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?J Endocrinol Invest20113454455121427524
   PubMed Web of Science ®Google Scholar
• KoroCELeeBHBowlinSJAntidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United StatesClin Ther2009312608261720110005
   PubMed Web of Science ®Google Scholar
• SnyderRWBernsJSUse of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney diseaseSemin Dial20041736537015461745
   PubMed Web of Science ®Google Scholar
• MakRHImpact of end-stage renal disease and dialysis on glycemic controlSemin Dial2000134810740665
   PubMed Web of Science ®Google Scholar
• CryerPEHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetesDiabetologia20024593794812136392
   PubMed Web of Science ®Google Scholar
• AremRHypoglycemia associated with renal failureEndocrinol Metab Clin North Am1989181031212645122
   PubMed Web of Science ®Google Scholar
• FerranniniEGroopPHNauckMFiorettoPHachTThomasMThe Significance of the Kidney in DiabetesKonigswinter, Germanyinfill Kommunikation GmbH2012
   Google Scholar
• AbeMOkadaKSomaMAntidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practiceCurr Drug Metab201112576921303332
   PubMed Web of Science ®Google Scholar
• AhrenBSchweizerADejagerSVillhauerEBDunningBEFoleyJEMechanisms of action of the DPP-4 inhibitor vildagliptin in manDiabetes Obes Metab20111377578321507182
   PubMed Web of Science ®Google Scholar
• AhrenBSchweizerADejagerSVildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab2009941236124319174497
   PubMed Web of Science ®Google Scholar
• DejagerSSchweizerAFoleyJEEvidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitusVasc Health Risk Manag2012833934822661900
   PubMedGoogle Scholar
• DejagerSRazacSFoleyJESchweizerAVildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res20073921822317373638
   PubMed Web of Science ®Google Scholar
• GokeBHershonKKerrDEfficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metforminHorm Metab Res20084089289518726829
   PubMed Web of Science ®Google Scholar
• Pi-SunyerFXSchweizerAMillsDDejagerSEfficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetesDiabetes Res Clin Pract20077613213817223217
   PubMed Web of Science ®Google Scholar
• SchweizerACouturierAFoleyJEDejagerSComparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naïve patients with type 2 diabetesDiabet Med20072495596117509069
   PubMed Web of Science ®Google Scholar
• BosiECamisascaRPColloberCRochotteEGarberAJEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care20073089089517277036
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMACamisascaRPCressierFCouturierADejagerSEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab2007917518517300593
   PubMed Web of Science ®Google Scholar
• GarberAJFoleyJEBanerjiMAEffects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylureaDiabetes Obes Metab2008101047105618284434
   PubMed Web of Science ®Google Scholar
• GarberAJSchweizerABaronMARochotteEDejagerSVildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab2007916617417300592
   PubMed Web of Science ®Google Scholar
• BolliGDottaFRochotteECohenSEEfficacy and tolerability of vildagliptin versus. pioglitazone when added to metformin: a 24-week, randomized, double-blind studyDiabetes Obes Metab200810829018034842
   PubMed Web of Science ®Google Scholar
• FonsecaVSchweizerAAlbrechtDBaronMAChangIDejagerSAddition of vildagliptin to insulin improves glycaemic control in type 2 diabetesDiabetologia2007501148115517387446
   PubMed Web of Science ®Google Scholar
• KothnyWFoleyJKozlovskiPShaoQGallwitzBLukashevichVImproved glycemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitusDiab Obes Metab1052012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• LukashevichVSchweizerAShaoQGroopPHKothnyWSafety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trialDiabetes Obes Metab20111394795421733061
   PubMed Web of Science ®Google Scholar
• KothnyWShaoQGroopPHLukashevichVOne-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairmentDiabetes Obes Metab2012141032103922690943
   PubMed Web of Science ®Google Scholar
• AhrenBGomisRStandlEMillsDSchweizerATwelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetesDiabetes Care2004272874288015562200
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSBosiEComparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Obes Metab20091180481219476473
   PubMed Web of Science ®Google Scholar
• RiddleMUmpierrezGDiGenioAZhouRRosenstockJContributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetesDiabetes Care2011342508251422028279
   PubMed Web of Science ®Google Scholar
• MillerCDPhillipsLSZiemerDCGallinaDLCookCBEl-KebbiIMHypoglycemia in patients with type 2 diabetes mellitusArch Intern Med20011611653165911434798
   PubMed Web of Science ®Google Scholar
• AmielSADixonTMannRJamesonKHypoglycaemia in type 2 diabetesDiabet Med20082524525418215172
   PubMed Web of Science ®Google Scholar
• LeeseGPWangJBroomhallJFrequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource useDiabetes Care2003261176118012663593
   PubMed Web of Science ®Google Scholar
• VilsbollTKrarupTMadsbadSHolstJJBoth GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjectsRegul Pept200311411512112832099
   PubMed Web of Science ®Google Scholar
• KreymannBWilliamsGGhateiMABloomSRGlucagon-like peptide-1 7-36: a physiological incretin in manLancet19872130013042890903
   PubMed Web of Science ®Google Scholar
• NauckMAKleineNOrskovCHolstJJWillmsBCreutzfeldtWNormalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patientsDiabetologia1993367417448405741
   PubMed Web of Science ®Google Scholar
• MeierJJGallwitzBSiepmannNGastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemiaDiabetologia20034679880112764578
   PubMed Web of Science ®Google Scholar
• DunningBEFoleyJEAhrenBAlpha cell function in health and disease: influence of glucagon-like peptide-1Diabetologia2005481700171316132964
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia2012551577159622526604
   PubMed Web of Science ®Google Scholar
• CryerPEHypoglycemia is the limiting factor in the management of diabetesDiabetes Metab Res Rev199915424610398545
   PubMed Web of Science ®Google Scholar
• CryerPEHypoglycemia: still the limiting factor in the glycemic management of diabetesEndocr Pract20081475075618996798
   PubMedGoogle Scholar